Loss of CD4+ T Cells in Human Immunodeficiency Virus Type 1-infected Chimpanzees is Associated with Increased Lymphocyte Apoptosis
Overview
Affiliations
Supportive evidence that apoptosis contributes to loss of CD4+ lymphocytes in human immunodeficiency virus type 1 (HIV-1)-infected humans comes from an apparent lack of abnormal apoptosis in apathogenic lentivirus infections of nonhuman primates, including HIV-1 infection of chimpanzees. Two female chimpanzees were inoculated, one cervically and the other intravenously, with HIV-1 derived from the LAI/LAV-1b strain, which was isolated from a chimpanzee infected with the virus for 8 years. Within 6 weeks of infection, both recipient chimpanzees developed a progressive loss of CD4+ T cells which correlated with persistently high viral burdens and increased levels of CD4+ T-cell apoptosis both in vitro and in vivo. Lymph nodes from both animals also revealed evidence of immune hyperactivation. Intermediate levels of T-cell apoptosis in both peripheral blood and lymph nodes were seen in a third chimpanzee that had been infected with the LAI/LAV-1b strain for 9 years; this animal has maintained depressed CD4/CD8 T-cell ratios for the last 3 years. Similar analyses of cells from 4 uninfected animals and 10 other HIV-1-infected chimpanzees without loss of CD4+ cells revealed no difference in levels of apoptosis in these two control groups. These results demonstrate a correlation between immune hyperactivation, T-cell apoptosis, and chronic loss of CD4+ T cells in HIV-1-infected chimpanzees, providing additional evidence that apoptosis is an important factor in T-cell loss in AIDS. Furthermore, the results show that some HIV-1 strains are pathogenic for chimpanzees and that this species is not inherently resistant to HIV-1-induced disease.
Chaudhary O, Narayan V, Lelis F, Linz B, Watkins M, Veazey R PLoS Pathog. 2018; 14(8):e1007268.
PMID: 30161247 PMC: 6135519. DOI: 10.1371/journal.ppat.1007268.
T cell interleukin-15 surface expression in chimpanzees infected with human immunodeficiency virus.
Rodriguez A, Hodara V, Murthy K, Morrow L, Sanchez M, Bienvenu A Cell Immunol. 2014; 288(1-2):24-30.
PMID: 24565973 PMC: 4373471. DOI: 10.1016/j.cellimm.2014.01.009.
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.
Gill A, Kolson D Crit Rev Immunol. 2013; 33(4):307-59.
PMID: 23971529 PMC: 3753696. DOI: 10.1615/critrevimmunol.2013007247.
Viral dynamics model with CTL immune response incorporating antiretroviral therapy.
Wang Y, Zhou Y, Brauer F, Heffernan J J Math Biol. 2012; 67(4):901-34.
PMID: 22930342 DOI: 10.1007/s00285-012-0580-3.
Coreceptor use in nonhuman primate models of HIV infection.
Sina S, Ren W, Cheng-Mayer C J Transl Med. 2011; 9 Suppl 1:S7.
PMID: 21284906 PMC: 3105507. DOI: 10.1186/1479-5876-9-S1-S7.